These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 24832787)

  • 1. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
    Rack B; Schindlbeck C; Jückstock J; Andergassen U; Hepp P; Zwingers T; Friedl TW; Lorenz R; Tesch H; Fasching PA; Fehm T; Schneeweiss A; Lichtenegger W; Beckmann MW; Friese K; Pantel K; Janni W;
    J Natl Cancer Inst; 2014 May; 106(5):. PubMed ID: 24832787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
    Hepp P; Andergassen U; Jäger B; Trapp E; Alunni-Fabbroni M; Friedl TW; Hecker N; Lorenz R; Fasching P; Schneeweiss A; Fehm T; Janni W; Rack B
    Anticancer Res; 2016 Sep; 36(9):4771-6. PubMed ID: 27630326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
    Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
    Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    Trapp E; Janni W; Schindlbeck C; Jückstock J; Andergassen U; de Gregorio A; Alunni-Fabbroni M; Tzschaschel M; Polasik A; Koch JG; Friedl TWP; Fasching PA; Haeberle L; Fehm T; Schneeweiss A; Beckmann MW; Pantel K; Mueller V; Rack B; Scholz C;
    J Natl Cancer Inst; 2019 Apr; 111(4):380-387. PubMed ID: 30312434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
    Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
    J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Value of Circulating Tumor Cells for Evaluating Short- and Long-Term Efficacy of Chemotherapy for Breast Cancer.
    Ma S; Ling F; Gui A; Chen S; Sun Y; Li Z
    Med Sci Monit; 2017 Oct; 23():4808-4816. PubMed ID: 28986517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.
    Juan O; Vidal J; Gisbert R; Muñoz J; Maciá S; Gómez-Codina J
    Clin Transl Oncol; 2014 Jul; 16(7):637-43. PubMed ID: 24217975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer.
    Janni WJ; Rack B; Terstappen LW; Pierga JY; Taran FA; Fehm T; Hall C; de Groot MR; Bidard FC; Friedl TW; Fasching PA; Brucker SY; Pantel K; Lucci A
    Clin Cancer Res; 2016 May; 22(10):2583-93. PubMed ID: 26733614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
    de Gregorio A; Häberle L; Fasching PA; Müller V; Schrader I; Lorenz R; Forstbauer H; Friedl TWP; Bauer E; de Gregorio N; Deniz M; Fink V; Bekes I; Andergassen U; Schneeweiss A; Tesch H; Mahner S; Brucker SY; Blohmer JU; Fehm TN; Heinrich G; Lato K; Beckmann MW; Rack B; Janni W
    Breast Cancer Res; 2020 Oct; 22(1):111. PubMed ID: 33097092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
    von Minckwitz G; Rezai M; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Blohmer JU; Costa SD; Jackisch C; Paepke S; Schneeweiss A; Kümmel S; Denkert C; Mehta K; Loibl S; Untch M
    Ann Oncol; 2014 Jan; 25(1):81-9. PubMed ID: 24273046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study.
    Du KY; Wu S; Ma X; Liu Y
    Breast Cancer Res Treat; 2024 Oct; 207(3):517-527. PubMed ID: 38990453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
    Bedognetti D; Sertoli MR; Pronzato P; Del Mastro L; Venturini M; Taveggia P; Zanardi E; Siffredi G; Pastorino S; Queirolo P; Gardin G; Wang E; Monzeglio C; Boccardo F; Bruzzi P
    J Natl Cancer Inst; 2011 Oct; 103(20):1529-39. PubMed ID: 21921285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University).
    Sakr H; Hamed RH; Anter AH; Yossef T
    Med Oncol; 2013 Mar; 30(1):457. PubMed ID: 23322524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer.
    Goodman CR; Seagle BL; Friedl TWP; Rack B; Lato K; Fink V; Cristofanilli M; Donnelly ED; Janni W; Shahabi S; Strauss JB
    JAMA Oncol; 2018 Aug; 4(8):e180163. PubMed ID: 29800954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.
    Xenidis N; Perraki M; Apostolaki S; Agelaki S; Kalbakis K; Vardakis N; Kalykaki A; Xyrafas A; Kakolyris S; Mavroudis D; Georgoulias V
    Br J Cancer; 2013 Feb; 108(3):549-56. PubMed ID: 23329233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
    Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
    J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.